JP2010514409A - ヒトの癌における鑑別式サイトカイン発現 - Google Patents

ヒトの癌における鑑別式サイトカイン発現 Download PDF

Info

Publication number
JP2010514409A
JP2010514409A JP2009515770A JP2009515770A JP2010514409A JP 2010514409 A JP2010514409 A JP 2010514409A JP 2009515770 A JP2009515770 A JP 2009515770A JP 2009515770 A JP2009515770 A JP 2009515770A JP 2010514409 A JP2010514409 A JP 2010514409A
Authority
JP
Japan
Prior art keywords
cytokine
tumor
agent
apoptotic
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009515770A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010514409A5 (https=
Inventor
スタッシィ ジョルジョ
ギーファース クリスティアン
ヒル オリヴァー
ティーマン マイノルフ
トダーロ マチルデ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apogenix AG
Original Assignee
Apogenix AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apogenix AG filed Critical Apogenix AG
Publication of JP2010514409A publication Critical patent/JP2010514409A/ja
Publication of JP2010514409A5 publication Critical patent/JP2010514409A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
JP2009515770A 2006-06-21 2007-06-21 ヒトの癌における鑑別式サイトカイン発現 Pending JP2010514409A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06012754 2006-06-21
PCT/EP2007/005480 WO2007147600A2 (en) 2006-06-21 2007-06-21 Differential il-4 and/or il-10 cytokine expression in human cancer

Publications (2)

Publication Number Publication Date
JP2010514409A true JP2010514409A (ja) 2010-05-06
JP2010514409A5 JP2010514409A5 (https=) 2010-06-17

Family

ID=38359749

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009515770A Pending JP2010514409A (ja) 2006-06-21 2007-06-21 ヒトの癌における鑑別式サイトカイン発現

Country Status (12)

Country Link
US (1) US20090324616A1 (https=)
EP (1) EP2041576B1 (https=)
JP (1) JP2010514409A (https=)
CN (1) CN101529253A (https=)
AT (1) ATE520032T1 (https=)
AU (1) AU2007263265A1 (https=)
BR (1) BRPI0713484A2 (https=)
CA (1) CA2656379A1 (https=)
DK (1) DK2041576T3 (https=)
ES (1) ES2371287T3 (https=)
RU (1) RU2009101783A (https=)
WO (1) WO2007147600A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020513574A (ja) * 2016-11-24 2020-05-14 ヒュベット バイオ, インコーポレイテッドHuvet Bio, Inc. 疾患の診断用組成物

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2646626A1 (en) * 2006-03-22 2007-09-27 Apogenix Gmbh Antibody specific for human il-4 for the treatment of cancer
US20100086515A1 (en) * 2006-07-06 2010-04-08 Apogenix Gmbh Human il-4 muteins in cancer therapy
EP3409686B1 (en) * 2012-07-18 2022-04-13 Apogenix AG Composition comprising a mixture of cd95-fc isoforms
WO2015138638A1 (en) 2014-03-11 2015-09-17 Theraly Pharmaceuticals, Inc. Long acting trail receptor agonists for treatment of autoimmune diseases
AU2015335607B2 (en) * 2014-10-24 2020-04-23 Calidi Biotherapeutics (Nevada), Inc. Combination immunotherapy approach for treatment of cancer
CN108135996B (zh) 2015-08-11 2022-06-21 卡利迪生物治疗有限公司 用以癌症治疗的天花疫苗
US11007251B2 (en) 2015-12-17 2021-05-18 The Johns Hopkins University Ameliorating systemic sclerosis with death receptor agonists
EA201892260A1 (ru) 2016-04-07 2019-03-29 Дзе Джонс Хопкинс Юниверсити Композиции и способы для лечения панкреатита и боли с применением агонистов рецептора смерти
CN111051349A (zh) * 2017-09-06 2020-04-21 弗雷德哈钦森癌症研究中心 Strep-tag特异性嵌合受体及其用途
US11505782B2 (en) 2018-06-04 2022-11-22 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU643427B2 (en) * 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
DE4137333A1 (de) * 1991-11-13 1993-05-19 W Prof Dr Sebald Therapeutische mittel, die antagonisten oder partielle agonisten des humanen interleukin 4 sind oder diese enthalten, hil-4-mutantenproteine sowie vefahren zu deren herstellung
US6534051B1 (en) * 1992-11-20 2003-03-18 University Of Medicine And Dentistry Of New Jersey Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins
WO1995007301A1 (en) 1993-09-07 1995-03-16 Smithkline Beecham Corporation Recombinant il4 antibodies useful in treatment of il4 mediated disorders
DE4423131A1 (de) * 1994-07-01 1996-01-04 Bayer Ag Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4
AU686816B2 (en) * 1994-07-05 1998-02-12 Steeno Research Group A/S Immunomodulators
HUT76369A (en) * 1994-07-29 1997-08-28 Smithkline Beecham Corp Novel soluble protein compounds
US6664227B1 (en) * 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
US5710023A (en) * 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
US20030124125A1 (en) * 1996-04-05 2003-07-03 South Alabama Medical Science Foundation Oncofetal antigen specific T-lymphocyte mediated immune response: manipulation and uses of oncofetal antigen specific CD4, CD8 cytotoxic and suppressor T cells and interleukin-10
US6028176A (en) * 1996-07-19 2000-02-22 Bayer Corporation High-affinity interleukin-4 muteins
CA2309598A1 (en) * 1997-11-10 1999-05-20 Mochida Pharmaceutical Co., Ltd. Preventives and remedies for diffuse lung disease
JPH11312463A (ja) * 1998-04-28 1999-11-09 Hitachi Ltd 配線基板およびそれを用いたガス放電型表示装置
WO2001074388A1 (en) * 2000-03-31 2001-10-11 Idec Pharmaceuticals Corporation Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma
AU2001273413A1 (en) * 2000-07-12 2002-01-21 Immunex Corporation Method for treating cancer using an interleukin- 4 antagonist
US20040023338A1 (en) * 2001-10-26 2004-02-05 Heavner George A. IL-4 mutein proteins, antibodies, compositions, methods and uses
CA2464695A1 (en) * 2001-10-26 2003-05-01 Centocor, Inc. Il-13 mutein proteins, antibodies, compositions, methods and uses
EP1444989A1 (en) * 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensitizing cells for apoptosis by selectively blocking cytokines
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
EP1824886B1 (en) * 2004-11-17 2010-12-22 Amgen Inc. Fully human monoclonal antibodies to il-13
US20070122855A1 (en) * 2005-11-28 2007-05-31 Targetgen Inc. Methods for diagnosing hepatocellular carcinoma
CA2646626A1 (en) * 2006-03-22 2007-09-27 Apogenix Gmbh Antibody specific for human il-4 for the treatment of cancer
US20100086515A1 (en) * 2006-07-06 2010-04-08 Apogenix Gmbh Human il-4 muteins in cancer therapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6012032476; Ｃａｎｃｅｒ　Ｒｅｓ Ｖｏｌ．６６，　Ｎｏ．３, 20060201, ｐ．１４９１-１４１９ *
JPN6012032478; Ｔｈｅ　Ｊｏｕｒｎａｌ　ｏｆ　Ｉｍｍｕｎｏｌｏｇｙ Ｖｏｌ．１７２, 2004, ｐ．５４６７-５４７７ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020513574A (ja) * 2016-11-24 2020-05-14 ヒュベット バイオ, インコーポレイテッドHuvet Bio, Inc. 疾患の診断用組成物

Also Published As

Publication number Publication date
WO2007147600A2 (en) 2007-12-27
EP2041576A2 (en) 2009-04-01
BRPI0713484A2 (pt) 2012-11-06
EP2041576B1 (en) 2011-08-10
RU2009101783A (ru) 2010-07-27
ATE520032T1 (de) 2011-08-15
DK2041576T3 (da) 2011-12-05
CN101529253A (zh) 2009-09-09
US20090324616A1 (en) 2009-12-31
CA2656379A1 (en) 2007-12-27
AU2007263265A1 (en) 2007-12-27
ES2371287T3 (es) 2011-12-29
WO2007147600A3 (en) 2008-04-10

Similar Documents

Publication Publication Date Title
JP2010514409A (ja) ヒトの癌における鑑別式サイトカイン発現
Cui et al. CD147 receptor is essential for TFF3-mediated signaling regulating colorectal cancer progression
Wei et al. Tumor microenvironment regulation by the endoplasmic reticulum stress transmission mediator Golgi protein 73 in mice
US20210079114A1 (en) Therapeutic and diagnostic target for cancer comprising dll3 binding reagents
DK2533047T3 (en) CCR4 as a therapeutic target for cancer
EP1469879B1 (en) Diagnosis and therapy of antibody-mediated inflammatory autoimmune disorders
Gao et al. CLDN18. 2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18. 2-expressing tumor-directed T-cell activation
AU2015206603B2 (en) Compositions and methods for identification, assessment, prevention, and treatment of melanoma using PD-L1 isoforms
Schinagl et al. Oxidized macrophage migration inhibitory factor is a potential new tissue marker and drug target in cancer
Matsuda et al. Fibroblast growth factor receptor 2 IIIc as a therapeutic target for colorectal cancer cells
CN111741752A (zh) Gpcr异聚体抑制剂及其用途
US20090214521A1 (en) Bone morphogenetic protein-2 in the treatment and diagnosis of cancer
JP2014505239A (ja) 癌の治療または検出のための抗ｃｘｃｌ１３および抗ｃｘｃｒ５抗体の使用
CN104755496A (zh) 作为癌症治疗和诊断靶标的ly75
CN121609797A (zh) 使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法
CN110709102A (zh) 低密度脂蛋白受体相关蛋白5抑制阻抑肿瘤形成
US20120015352A1 (en) Method of determining sensitivity of human or non-human animal cells to an iap antagonist
EP2063904A1 (en) Methods involving lef-1 regulation and use of lef-1 or compounds altering lef-1 signalling for treating or preventing diseases
EP2958590B1 (en) Bispecific antibody binding to naaladl2 and cd3 for use as a therapeutic in treating prostate cancer
CN112740043A (zh) Vista受体
CN117940124A (zh) Sting激动剂的生物标志物及其使用方法
US8652478B2 (en) Method for treating cancer by administering antibody to ephrin type-A receptor 7
US20150210770A1 (en) Therapeutic and diagnostic target
JP7012363B2 (ja) がん患者におけるｆｓｔｌ１阻害剤による治療効果を予測するためのバイオマーカー
WO2003056340A2 (en) Fadd proteins, phosphorylated p38-mapk and fasl as tumour markers

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100414

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100414

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20101227

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20101228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120628

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120926

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121003

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121026

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121102

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121128

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121205

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130306